Frank Laukien on cost savings
From Bruker Corporation BRKR Q3 2025 Earnings Call · · Fyfull
“Our major cost savings initiatives announced last quarter are progressing very well towards the high end of our $100 million to $120 million cost-down targets for 2026 and they are expected to deliver significant margin expansion and double-digit EPS growth in 2026.”
On , Frank Laukien, Chairman, Chief Executive Officer & President at BRUKER CORP, spoke about cost savings during Bruker Corporation BRKR Q3 2025 Earnings Call on Fyfull.
About Frank Laukien
Frank Laukien, chairman, president, and CEO of Bruker Corporation, discussed the company's third-quarter 2025 earnings on November 10, 2025. He reported that revenues and earnings were down year-over-year, which he attributed to weaker academic and research instruments demand in the first half of the year. Laukien noted that the company's scientific instrument segment book-to-bill ratio exceeded 1.0x for the first time in several quarters, driven by stronger Q3 order performance. He stated that cost savings initiatives are progressing toward the high end of a $100 million to $120 million target for 2026)Skip, and that organic scientific instruments orders in China increased by a double-digit percentage year-over-year. Laukien also mentioned that the company is seeing growth in automated, digitized labs for AI, spatial biology, proteomics, and diagnostics. He said that a potential U.S. government shutdown is not formally baked into the company's outlook, but that a prolonged shutdown could delay grants, orders, and installations. Separately, Laukien has been involved in scientific discussions on cancer and evolution. In a September 2021 symposium, he argued that cancer is an evolutionary phenomenon that involves not only somatic mutations but also genome and karyotype rearrangement processes. He emphasized the importance of studying the host and immune system for early detection, and described epigenetics and post-translational modifications such as phosphorylation and glycosylation as playing a significant role in cancer evolution. Laukien stated that the symposium aimed to improve understanding of cancer cell evolution and to contribute to progress in prevention, early screening, diagnostics, and therapy.